As of 1 December 2024, combination chemotherapy medicines, Opdualag and Vyxeos, will be transitioned from the Highly Specialised Drugs Program to the Efficient Funding of Chemotherapy Program, consistent with recommendations by the Pharmaceutical Benefits Advisory Committee.

Please visit the FAQ for combination chemotherapy medicines for further details on this transition.